//

Understanding gene therapy challenges in duchenne muscular dystrophy

Exploring gene therapy challenges in Duchenne muscular dystrophy and how novel beta glucans offer new hope in slowing disease progression.

Correcting the genetic inborn defects using gene therapy is challenging. Duchenne Muscular Dystrophy (DMD) affects male children and has a global incidence of one in 3500~5000 male births. The patients succumb to early death due to a non-functional locomotor system in their teenage, followed by respiratory and cardiac muscle failure in their twenties to thirties.

This condition arises due to the absence of a protein called dystrophin, which is crucial for the smooth functioning of the body’s muscles. Without dystrophin, muscle movements become irregular and damaging, gradually leading to a decline in bodily functions and early death. When dystrophin is defective or missing, these irregular movements during locomotion or respiration trigger an abnormal tissue response similar to the body’s reaction to injury, typically initiating a healing process.

In the case of an injury, the process concludes once healing is complete. However, in Duchenne Muscular Dystrophy (DMD), this injury-like response continuously occurs due to muscle dysfunction every time the affected individual moves, leading to ongoing microscopic muscle damage. Over time, this repetitive injury causes muscle stiffening, known as fibrosis, resulting in a severe loss of muscle mobility.

Given this disease background, addressing the symptoms of DMD without targeting the root genetic cause is akin to trying to extinguish flames with water or foam without shutting off the source of the fire. While disease-modifying treatments that slow the disease’s progression exist, they often come with unavoidable adverse effects.

Innovative approach: neu REFIX beta-glucans in combating DMD

Our research focused on comparing two novel beta glucans produced by different strains of the yeast Aureobasidium pullulans. Although these beta glucans are exopolysaccharides from the same species, they exhibit distinct biological effects due to their physical and chemical differences. These yeasts are known for their high thermotolerance and adaptability, and they produce Beta-1,3/1,6 glucans, which we successfully standardized in terms of dosage. Moreover, we could produce these glucans without including any allergenic ingredients.

After confirming their safety as food additives, we conducted animal studies, particularly in inflammatory disease models like liver fibrosis. These studies revealed the anti-fibrotic effects of the Neu REFIX beta- glucan product, produced as an exopolysaccharide by the N-163 strain of Aureobasidium pullulans. This discovery prompted us to search for a target disease to which this solution could be applied. We eventually identified Duchenne Muscular Dystrophy (DMD) as a potential target, given the lack of definitive treatments and the limitations of current disease-modifying approaches regarding adverse effects and long-term outcomes.

Duchenne muscular dystrophy (DMD) mouse model

In an animal study using a Duchenne Muscular Dystrophy (DMD) mouse model, specifically mdx mice, oral consumption of Neu REFIX beta glucans as a standalone agent significantly reduced skeletal muscle fibrosis. These findings are highly encouraging, as our goal is to incorporate this food supplement as an adjuvant to standard treatment regimens. While Neu REFIX beta glucans have proven safe and effective, we believe their addition to conventional treatments could further enhance the benefits of current disease-modifying approaches. This potential has already been demonstrated in a clinical study involving DMD patients.

Neu REFIX compounds work by safely and effectively preventing an overactive immune response to the minor, repetitive injuries that occur in the muscles of DMD patients and an increase in their plasma dystrophin. This research marks a significant step toward developing a definitive treatment for DMD by providing a safer, more efficient tool to slow disease progression. The simplicity of an orally consumable food supplement, as opposed to painful intramuscular or intravenous injections, makes this approach particularly appealing.

Potential applications of neu REFIX in autoimmune diseases

Given the demonstrated safety and efficacy of this compound in treating DMD, we are now expanding our research to explore its potential applications in autoimmune diseases, where the body’s immune system mistakenly targets its cells, leading to similar injury-like responses.

Our research has uncovered a simpler food supplement with remarkable potential as a stop-gap remedy for this rare disease, helping to extend the lives of affected individuals until a definitive solution is found. With further in-depth research, its application could be expanded to other diseases where similar immune modulation could serve as a valuable tool in disease management.

πŸ”¬πŸ§«πŸ§ͺπŸ”πŸ€“πŸ‘©β€πŸ”¬πŸ¦ πŸ”­πŸ“š

Journal reference

Raghavan, K., Dedeepiya, V. D., Srinivasan, S., Pushkala, S., Bharatidasan, S. S., Ikewaki, N., … & Abraham, S. J. (2023). Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1, 3-1, 6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study. IBRO Neuroscience reports, 15, 90-99. https://doi.org/10.1016/j.ibneur.2023.06.007

Dr. Raghavan is a Pediatric Neurologist and Chief Consultant at JAICARE Hospital, Madurai, India. After gaining experience with the UK's National Health Service (NHS), Dr. Raghavan returned to India to focus on groundbreaking research in Duchenne Muscular Dystrophy (DMD). He played a pivotal role in pioneering the first exon skipping gene therapy for a child with DMD in India. Currently, Dr. Raghavan spearheads research as the principal investigator on several clinical trials. These trials explore the use of biological response modifiers to treat DMD and other rare childhood diseases like Aicardi Gautier syndrome. Dr. Raghavan's dedication and expertise position him as a frontrunner in advancing treatments for these challenging conditions.

Prof. Ikewaki is a distinguished professor at Kyushu University of Medical Sciences, where he leads the Laboratory of Clinical Immunology within the Department of Animal Pharmaceutical Science, School of Pharmaceutical Sciences. With extensive expertise in immunology, monoclonal antibodies, and antigens, Prof. Ikewaki is renowned for his groundbreaking research on biological response modifier glucans derived from novel strains of Aureobasidium pullulans. His pioneering work has contributed to significant advancements in understanding and treating various diseases, including pancreatic tumors, multiple sclerosis, Duchenne muscular dystrophy, Parkinson's disease, autism, metabolic disorders, and immunological disorders. Through his innovative approach, Prof. Ikewaki has contributed significantly to the translation of glucans to therapeutic settings.

Dr. Abraham is a Phsyician-Scientist trained in Cardiac Surgery and diversified into developing novel solutions in several specialities of healthcare in the domains of stem cells, nanomaterials, biological response modifier glucans and regenerative medicine. Currently based in Yamanashi-ken, Japan, Dr. Abraham serves as a faculty at the Centre for Advancing Clinical Research in University of Yamanashi and is a co-founder and director of GN Corporation Co. Ltd. in Japan, and the Nichi-In Centre for Regenerative Medicine (NCRM) in India. Dr. Abraham’s research interests span immune system evolution, gut-brain axis, neurodegenerative diseases and in vitro cellular senescence including implications of microgravity.